Log In
Print this Print this

Egranli, balugrastim (formerly Neugranin)

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionLong-acting recombinant human granulocyte colony-stimulating factor (G-CSF; CSF3) fused to human albumin
Molecular Target Granulocyte colony-stimulating factor (G-CSF) receptor (CSF3R) (CD114)
Mechanism of ActionGranulocyte colony stimulating factor (G-CSF) receptor (CD114) agonist
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentRegistration
Standard IndicationNeutropenia
Indication DetailsTreat chemotherapy-induced neutropenia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today